Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2016 Review: Despite Political Woes, Korea Pro-Pharma Policies Stay Intact

Executive Summary

2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.

You may also be interested in...



Korea Plans Breakthrough System To Encourage Innovation

Following up on its May announcement of a conditional approval scheme to shorten R&D and approval periods, and aiming to ensure the prompt and stable supply of life-saving drugs, South Korea is planning a new law on breakthrough therapies and for drugs for public health crises.

Korean Regulatory Overhaul To Cut Drug RnD, Approval Time

The South Korean government has unveiled a series of regulatory reforms that are designed to step up the competitiveness of the pharma industry and supply drugs in time for public health emergencies.

Korea Accelerating Efforts To Develop, Launch Orphan Drugs

South Korea's Ministry of Food and Drug Safety has issued revised rules to ease the designation and approval of orphan drugs. The changes are expected to create an environment that would support aggressive development of orphan drugs by the domestic pharmaceutical industry and result in more treatment options for patients.

Topics

UsernamePublicRestriction

Register

PS119667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel